Literature DB >> 17343323

Ligands for programmed cell death 1 gene in patients with systemic lupus erythematosus.

Shu-Chen Wang1, Chia-Hui Lin, Tsan-Teng Ou, Cheng-Chin Wu, Wen-Chan Tsai, Chaur-Jong Hu, Hong-Wen Liu, Jeng-Hsien Yen.   

Abstract

OBJECTIVE: To investigate the role of ligands for programmed cell death 1 (PD-L) in the pathogenesis of systemic lupus erythematosus (SLE).
METHODS: One hundred sixty-four patients with SLE and 160 healthy controls were enrolled in our study. The PD-L1 and PD-L2 polymorphisms were determined by polymerase chain reaction (PCR)/direct sequencing or restriction fragment length polymorphism (RFLP)-PCR.
RESULTS: The genotype distributions of PD-L2 47103 C/T polymorphisms in patients with SLE were significantly different from those of the controls (p = 0.003). The genotype frequency of PD-L2 47103 T/T, in comparison with 47103 C/C, was significantly increased in patients with SLE when compared with that of the controls (odds ratio 2.5, 95% confidence interval 1.4-4.4, p = 0.001). A similar finding could also be found in the allele frequency of PD-L2 47103 T (SLE vs control, OR 1.7, 95% CI 1.3-2.4, p = 0.001). There were no significant differences in the genotype and allele frequencies of PD-L1 polymorphisms between the patients and controls.
CONCLUSION: PD-L2 47103 T may be associated with susceptibility to SLE in Taiwan.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17343323

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

Review 1.  L2pB1: a new player in autoimmunity.

Authors:  Xuemei Zhong; Thomas L Rothstein
Journal:  Mol Immunol       Date:  2010-12-31       Impact factor: 4.407

Review 2.  Targeting the programmed cell death-1 pathway in rheumatoid arthritis.

Authors:  Sabina Sandigursky; Gregg J Silverman; Adam Mor
Journal:  Autoimmun Rev       Date:  2017-05-29       Impact factor: 9.754

Review 3.  T cell costimulation and coinhibition: genetics and disease.

Authors:  Lisa Scandiuzzi; Kaya Ghosh; Xingxing Zang
Journal:  Discov Med       Date:  2011-08       Impact factor: 2.970

4.  Polymorphisms of genes for programmed cell death 1 ligands in patients with rheumatoid arthritis.

Authors:  Shu-Chen Wang; Chia-Hui Lin; Ruei-Nian Li; Tsan-Teng Ou; Cheng-Chin Wu; Wen-Chan Tsai; Hong-Wen Liu; Jeng-Hsien Yen
Journal:  J Clin Immunol       Date:  2007-06-28       Impact factor: 8.317

5.  Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1.

Authors:  N Mozaffarian; A E Wiedeman; A M Stevens
Journal:  Rheumatology (Oxford)       Date:  2008-07-23       Impact factor: 7.580

6.  Association of a PD-L2 Gene Polymorphism with Chronic Lymphatic Filariasis in a South Indian Cohort.

Authors:  Gopinath Venugopal; Noëlle L O'Regan; Subash Babu; Ralf R Schumann; Aparna Srikantam; Roswitha Merle; Susanne Hartmann; Svenja Steinfelder
Journal:  Am J Trop Med Hyg       Date:  2019-02       Impact factor: 2.345

7.  Lack of an association of PD-1 and its ligand genes with Behcet's disease in a Chinese Han population.

Authors:  Qianli Meng; Haike Guo; Shengping Hou; Zhengxuan Jiang; Aize Kijlstra; Peizeng Yang
Journal:  PLoS One       Date:  2011-10-19       Impact factor: 3.240

8.  TNF-α and TGF-β counter-regulate PD-L1 expression on monocytes in systemic lupus erythematosus.

Authors:  Jing-Ni Ou; Alice E Wiedeman; Anne M Stevens
Journal:  Sci Rep       Date:  2012-03-02       Impact factor: 4.379

Review 9.  From single nucleotide polymorphisms to constant immunosuppression: mesenchymal stem cell therapy for autoimmune diseases.

Authors:  Raghavan Chinnadurai; Edmund K Waller; Jacques Galipeau; Ajay K Nooka
Journal:  Biomed Res Int       Date:  2013-11-19       Impact factor: 3.411

10.  Octamer binding protein 2 (Oct2) regulates PD-L2 gene expression in B-1 cells through lineage-specific activity of a unique, intronic promoter.

Authors:  H Kaku; T L Rothstein
Journal:  Genes Immun       Date:  2009-08-27       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.